March 08, 2016
Wellesley, Mass., March 8, 2016 – RNA Sequencing (RNA-Seq) produces more data in less time and with less cost than with microarray, thanks to high-throughput sequencing instruments. BCC Research reveals in its new report that the RNA-Seq instruments segment, the foundation for other RNA-Seq market segments, depends on the development of new and improved high throughput sequencing technologies.
RNA sequencing is a revolutionary method for the study of the transcriptome. Transcriptomics is the study of transcriptome, the complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell, using high-throughput methods. The market comprises four segments: RNA-Seq instruments; RNA-Seq tools and reagents; RNA-Seq data analysis; and RNA-Seq services.
The global market should total nearly $2.1 billion in 2020, up from $1 billion in 2015, reflecting a five-year compound annual growth rate (CAGR) of 14.9%. Tools and reagents, the largest segment, should total more than $566.8 million and $1 billion in 2015 and 2020, respectively, demonstrating a five-year CAGR of 13%. Services, the fastest-growing segment with an anticipated five-year CAGR of 22%, should reach $170.5 million and $460.5 million in 2015 and 2020, respectively, as RNA-Seq assumes greater adoption.
As a segment, the RNA–Seq instrument should experience a five-year CAGR of 9.1%, reaching $354.7 million in 2020. The market is dynamic and a new technology could be revolutionary and dramatically change not only the competitive landscape of the sequencing instrument segment, but also other derivative segments. Sequencers producing more accurate, longer sequences in a faster and cheaper fashion will achieve a competitive advantage.
Because the sequencing instruments segment determines how the other three segments develop, it is the core market segment. The other three are derivative segments. However, sequencing instruments is not the biggest, or the fastest growing sector, among the four. The RNA-Seq market can be dramatically different 10 years later as many companies are working on sequencing technologies, especially those based on single-molecule or nano-pore technologies or 3GS. 3GS is theoretically more suitable for RNA-Seq. However, over the forecast period, the dominant status of next gene sequencing (NGS) should continue.
“Use of RNA-Seq should grow in clinical settings during the next five years to 10 years,” says BCC Research analyst Faqing Yuan. “But for now, basic biological or medical research rely on transcriptomics. Obtaining sequencing information will become cheaper, faster and more accurate. The real challenges and opportunities are to interpret the sequencing data and make biomedical connections. The data analysis and services segments will see the highest growth rates over the next five to 10 years.”
RNA Sequencing: Technologies and Global Markets (BIO147A) analyzes the industry by technology, by type, and by end-user application. The report examines emerging applications, trends, pricing considerations, R&D, government regulations, and competitive technologies. Analyses of global market drivers and trends, with data from 2014, 2015, and projections of CAGRs through 2020 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
RNA Sequencing: Technologies and Global Markets( BIO147A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.